A team of researchers at Texas A&M University has developed an experimental nasal spray that may help aging brains regain memory and function.
In a new study, scientists reported that the treatment reduced harmful brain inflammation and improved cognitive performance after only two doses.
The findings were published in the Journal of Extracellular Vesicles and are attracting attention because they suggest some effects of brain aging may not be permanent.
As people age, the brain often becomes less efficient. Many older adults experience memory loss, slower thinking, reduced attention, and difficulty learning new things. In more serious cases, aging can contribute to dementia and Alzheimer’s disease.
Scientists have spent years trying to understand why brain function declines with age. One major suspect is chronic inflammation inside the brain.
This slow, ongoing inflammation can quietly damage brain cells and interfere with communication between neurons. Researchers call this process neuroinflammaging, meaning age-related inflammation of the nervous system.
The Texas A&M team focused on finding a way to reduce this inflammation directly inside the brain.
The researchers created a treatment using extracellular vesicles, tiny natural particles released by cells. These particles act like microscopic delivery vehicles that carry biological information between cells.
The vesicles were filled with microRNAs, molecules that help regulate gene activity. Scientists say microRNAs can influence many important pathways involved in inflammation, cell repair, and brain function.
To deliver the treatment, the researchers used a nasal spray instead of injections or surgery.
This method allowed the therapy to bypass the brain’s protective barrier and move directly into brain tissue. Researchers believe this approach could make future treatments safer and easier for patients if proven effective.
Once the treatment reached the brain, it appeared to calm overactive immune responses linked to aging. The therapy reduced activity in inflammatory systems known as the NLRP3 inflammasome and cGAS-STING pathways, both strongly connected to chronic brain inflammation.
The treatment also improved the health of mitochondria inside brain cells.
Mitochondria are tiny structures that produce energy for cells. Brain cells require enormous amounts of energy to process information, form memories, and maintain communication networks. As the brain ages, mitochondrial damage can reduce energy production and contribute to cognitive decline.
The researchers believe restoring mitochondrial function may help brain cells recover their ability to work properly.
Behavioral testing in the study supported this idea. Subjects that received the treatment performed significantly better on memory and recognition tasks compared to untreated controls.
The treated subjects were better at recognizing familiar objects, identifying new items, and noticing changes in their surroundings.
Researchers also reported that the improvements lasted for several months after only two doses of the nasal spray.
According to the study authors, this long-lasting effect may indicate that the treatment helps activate the brain’s own repair systems rather than only providing temporary symptom relief.
The findings may eventually have important implications for diseases linked to aging, including dementia, Alzheimer’s disease, and possibly recovery after stroke.
The researchers say current dementia treatments mainly focus on managing symptoms and slowing decline. Very few therapies directly target the underlying biological causes of brain aging.
Because dementia rates are rising rapidly worldwide, scientists are urgently searching for new treatment approaches.
The study also produced another encouraging result. The therapy appeared to work similarly well in both sexes. Researchers say this consistency is relatively uncommon in biomedical studies and may improve the treatment’s future potential.
Even though the results are exciting, scientists stress that much more work remains before the nasal spray could ever become available for patients.
The research has not yet reached human clinical trials. Safety testing, dosage studies, and long-term evaluations will still be needed before researchers know whether the treatment can safely help people.
Scientists also want to understand whether the therapy could be combined with other treatments or used earlier to help prevent cognitive decline before severe symptoms appear.
Reviewing the findings carefully, the study represents an important step forward in brain aging research because it targeted several key aging mechanisms at once, including inflammation, mitochondrial dysfunction, and memory decline.
The noninvasive nasal delivery system also gives the treatment practical appeal for future medical use. However, because the research is still at a preclinical stage, it remains uncertain whether the same dramatic effects will appear in humans.
Larger future studies and clinical trials will be essential before any firm conclusions can be made. Still, the results offer new hope that some aspects of brain aging may eventually become treatable rather than simply accepted as an unavoidable part of growing older.
